Will the FDA approve a CRISPR gene-editing therapy for a new disease in 2026?

Market snapshot

• Yes53% now
• No47% now

Why it matters

Each new FDA nod for CRISPR expands the map of treatable genetic disease; 2026 approvals would signal whether the platform is moving beyond sickle cell into broader in vivo and ex vivo indications.

Resolution criteria

Resolves YES if the US FDA grants marketing approval in calendar year 2026 for a CRISPR or CRISPR-based gene-editing therapy for at least one disease indication not covered by any prior FDA-approved gene-editing product. Clinical holds or filings without approval resolve NO.

Timing